RE:Financing?Yes, the trial they profiled yesterday is much larger, and therfore even more expensive, than what they initially were talking about. But a financing is what makes the analyst aggressively promote a stock. For an example go look at the run-up to the $125 million NGM just raised this week. In the week before, analysts were stumbling over themselves tor aise their price targets drammatically on the stock in order to be part of the offering and warn a big commission check.
In TH's case, if they choose to raise money via a share or convert offering, it may not come until later this year since the NASH phase III is not starting until Q3. That will give them time to potentially have some cancer data out first, which if favorable, could lead to a huge spike in the share price. I half wonder if they intentionally are delaying the start of the NASH trial in odrer to have the option of raising money post some favorable cancer data.
They also may choose to do a partnership on either NASH, cancer or both. Depending onthe terms of that, they may not need a share offering or could get away with raising a smaller amount from selling shares. Which is another good reason to wait on the cancer data in order to determine how to raise money.
xena555 wrote: I may have missed a previous discussion on this, but aren't these guys going to have to rasie a bunch of money to conduct their trials? I'm wondering if that's why the analysts aren't being overly agressive right now.